Rheumatoid Arthritis Clinical Trial
Official title:
A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate
Verified date | November 2010 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Status | Completed |
Enrollment | 1052 |
Est. completion date | February 2009 |
Est. primary completion date | February 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of rheumatoid arthritis (RA) <=2 years; MTX naive or <=10 mg/wk for <=3 weeks. No dose within 3 months prior to informed consent. - C-Reactive Protein (CRP) >= 4.5 mg/L (after amendment) - Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive - Tender joints >=12 and swollen joints >=10 Exclusion Criteria: - Women and men who are not willing to use birth control - Diagnosed with other rheumatic disease - History of cancer within 5 years - Active tuberculosis - Treatment with another investigation drug within 28 days - Active bacterial or viral infection |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Local Institution | Malvern | Victoria |
Australia | Local Institution | Shenton Park | Western Australia |
Belgium | Local Institution | Antwerpen | |
Belgium | Local Institution | Bruxelles | |
Belgium | Local Institution | Bruxelles | |
Belgium | Local Institution | Hasselt | |
Belgium | Local Institution | Leuven | |
Brazil | Local Institution | Curitiba | Parana |
Brazil | Local Institution | Goiania | Goias |
Brazil | Local Institution | Porto Alegre | Rio Grande Do Sul |
Brazil | Local Institution | Rio De Janeiro - Rj | Rio De Janeiro |
Brazil | Local Institution | Sao Paulo | |
Brazil | Local Institution | Sao Paulo | |
Canada | Local Institution | Kitchener | Ontario |
Canada | Local Institution | Montreal | Quebec |
Canada | Local Institution | Quebec | |
Canada | Local Institution | Saskatoon | Saskatchewan |
Canada | Local Institution | Sherbrooke | Quebec |
Canada | Local Institution | St. John'S | Newfoundland and Labrador |
Canada | Local Institution | Toronto | Ontario |
Czech Republic | Local Institution | Prague 2 | |
France | Local Institution | Dijon | |
France | Local Institution | Montpellier Cedex 5 | |
France | Local Institution | Nice Cedex 03 | |
France | Local Institution | Strasbourg Cedex | |
Germany | Local Institution | Berlin | |
Germany | Local Institution | Hamburg | |
Germany | Local Institution | Leipzig | |
Germany | Local Institution | Leipzig | |
Italy | Local Institution | Jesi(Ancona) | |
Italy | Local Institution | Milano | |
Korea, Republic of | Local Institution | Anyang | |
Korea, Republic of | Local Institution | Daegu | |
Korea, Republic of | Local Institution | Daejeon | |
Korea, Republic of | Local Institution | Seoul | |
Korea, Republic of | Local Institution | Seoul | |
Korea, Republic of | Local Institution | Seoul | |
Korea, Republic of | Local Institution | Seoul | |
Mexico | Local Institution | Chihuahua | |
Mexico | Local Institution | Cuernavaca | Morelos |
Mexico | Local Institution | D.f. | Distrito Federal |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Leon | Guanajuato |
Mexico | Local Institution | Metepec | Estado De Mexico |
Mexico | Local Institution | Monterrey | Nuevo Leon |
Mexico | Local Institution | Morelia | Michioacan |
Mexico | Local Institution | San Luis Potosi | |
Netherlands | Local Institution | Amsterdam | |
Netherlands | Local Institution | Leiden | |
Netherlands | Local Institution | Nijmegen | |
Poland | Local Institution | Poznan | |
Poland | Local Institution | Poznan | |
Poland | Local Institution | Warszawa | |
Puerto Rico | Local Institution | Ponce | |
Russian Federation | Local Institution | Moscow | |
Russian Federation | Local Institution | Moscow | |
South Africa | Local Institution | Berea | Kwa Zulu Natal |
South Africa | Local Institution | Bloemfontein | Free State |
South Africa | Local Institution | Muckleneuk | Gauteng |
South Africa | Local Institution | Panorama | Western Cape |
South Africa | Local Institution | Pretoria | Gauteng |
Spain | Local Institution | A Coruna | |
Spain | Local Institution | Santander | |
Spain | Local Institution | Sevilla | |
United Kingdom | Local Institution | Glasgow | Lanarkshire |
United Kingdom | Local Institution | Leeds | North Yorkshire |
United Kingdom | Local Institution | Manchester | Greater Manchester |
United Kingdom | Local Institution | Newcastle | Northumberland |
United States | Arthritis Clinic Of Northern Virginia, P.C. | Arlington | Virginia |
United States | Walter F Chase Md Pa | Austin | Texas |
United States | Regional Rheumatology Associates | Binghamton | New York |
United States | Low Country Research Center | Charleston | South Carolina |
United States | Carolina Bone & Joint | Charlotte | North Carolina |
United States | Arthritis Assoc And Osteo Ctr Of Col Sprgs | Colorado Springs | Colorado |
United States | Osteoporosis And Clinical Trials Center | Cumberland | Maryland |
United States | Altoona Center For Clinical Research | Duncansville | Pennsylvania |
United States | Physicians East, Pa | Greenville | North Carolina |
United States | Malamet & Klein, Md, Pa | Hagerstown | Maryland |
United States | Talbert Medical Group | Huntington Beach | California |
United States | Rheumatology Associates Of North Alabama | Huntsville | Alabama |
United States | Diagnostic Rheumatology And Research | Indianapolis | Indiana |
United States | Arthritis Center Of Nebraska | Lincoln | Nebraska |
United States | Lion Research | Norman | Oklahoma |
United States | Health Research Of Oklahoma | Oklahoma City | Oklahoma |
United States | Lynn Health Sciences Institute | Oklahoma City | Oklahoma |
United States | Carolina Pharmaceutical Research | Statesville | North Carolina |
United States | New England Research Associates, Llc | Trumbull | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Russian Federation, South Africa, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 | Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of <2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 >5.1 = high disease activity; <=3.2 = low disease activity; <2.6 = remission. | Month 12 | No |
Primary | Mean Change From Baseline in Radiographic Total Score to Month 12 | To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. | Baseline, Month 12 | No |
Primary | Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. | Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. | Yes |
Primary | Number of Participants With Serious Adverse Events Reported During the Open-Label Period | SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. | Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. | Yes |
Primary | Number of Participants With SAEs With an Outcome of Death During the Open-label Period | Any untoward medical occurrence (SAE) that resulted in death | Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. | Yes |
Primary | Incidence Rates of Autoimmune Disorders in ABA-Treated Participants | The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event. | Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first). | Yes |
Primary | Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants | The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event. | Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first). | Yes |
Primary | Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants | The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event. | Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first). | Yes |
Primary | Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period | There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study. | Open-Label Period (Month 12 to Month 24) | Yes |
Primary | Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period | Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) >2x upper limit of normal (ULN) or if pretreatment (PRE-RX) >ULN then >3x PRE-RX; aspartate aminotransferase (AST) >3x ULN or if PRE-RX >ULN then >4x PRE-RX; alanine aminotransferase (ALT) >3x ULN or if PRE-RX >ULN then >4x PRE-RX; g-glutamyl transferase (GGT)>2x ULN or if PRE-RX >ULN then >3x PRE-RX; total bilirubin >2x ULN or if PRE-RX >ULN then >4x PRE-RX; blood urea nitrogen >2x PRE-RX; creatinine >1.5x PRE-RX. | Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. | Yes |
Primary | Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period | Marked abnormalities in hemoglobin >3 g/dL decrease from PRE-RX; hematocrit <0.75x PRE-RX; erythrocytes <0.75x PRE-RX; platelet count <0.67x lower limit of normal (LLN) or >1.5x ULN or if PRE-RX Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. |
Yes |
|
Secondary | Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12 | ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value [ie, CRP]. | Month 12 | No |
Secondary | Number of Participants With Major Clinical Response (MCR) at Month 12 | MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value [ie, CRP]). | Month 12 | No |
Secondary | Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12 | DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 >5.1=high disease activity; <3.2=low disease activity; <2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value. | Baseline, Month 12 | No |
Secondary | Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12 | Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline. | Month 12 | No |
Secondary | Adjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12 | The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value. | Baseline, Month 12 | No |
Secondary | Mean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12 | To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value | Baseline, Month 12 | No |
Secondary | Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA) | Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig [anti-abatacept antibody]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those < lowest reportable titer (<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those < lowest reportable titer (<25). | includes data up to approximately 85 days past the last dose of the double-blind period or start of the open-label period, whichever occurred first. | No |
Secondary | Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA | Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig [anti-abatacept antibody]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those < lowest reportable titer (<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those < lowest reportable titer (<25). | Includes open-label data up to approximately 85 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first. | No |
Secondary | Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24 | Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline. | Baseline, Month 24 | No |
Secondary | Mean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24 | To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value. | Baseline, Month 24 | No |
Secondary | Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24 | Participants with no radiographic progression (defined as change in score <=0 or <=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. | Baseline, Month 24 | No |
Secondary | Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12 | Participants with no radiographic progression ((defined as change in score <=0 or <=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. | Month 12, Month 24 | No |
Secondary | Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score) | Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. | Baseline, Month 12, Month 24 | No |
Secondary | Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period | AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. | Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first. | Yes |
Secondary | Number of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period | Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria | Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first. | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |